{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-019096","form_type":"8-K","ticker":"FEED","cik":"0001326706","company_name":"ENvue Medical, Inc.","filed_at":"2023-05-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.411810+00:00","generated_at":"2026-06-14T14:14:53.574820+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"NanoVibronix receives NASDAQ deficiency notice for minimum stockholders' equity","bullets":["Stockholders' equity of ~$2.2M as of March 31, 2023, is below NASDAQ's $2.5M minimum.","Company does not meet alternative compliance standards ($35M market value or $500K net income).","Must submit a plan to regain compliance by July 7, 2023; NASDAQ may grant up to 180-day extension.","Failure to regain compliance could lead to delisting of common stock from Nasdaq Capital Market.","Management intends to evaluate courses of action but provides no assurance of regaining compliance."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-019096","json":"https://secwatch.observer/filing/0001493152-23-019096.json","markdown":"https://secwatch.observer/filing/0001493152-23-019096.md","text":"https://secwatch.observer/filing/0001493152-23-019096.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326706/000149315223019096/0001493152-23-019096-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326706/000149315223019096/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T14:14:53.574820+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"66c979e4f90c6f5aaf542252f8c330106368b4d5","claim":"ENvue Medical, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"May 23, 2023, NanoVibronix, Inc. (the “Company”) received a letter from the Listing Qualifications Department of the NASDAQ Stock Market (“NASDAQ”) indicating that the Company no longer complies with the minimum stockholders’ equity requirement under NASDAQ Listing Rule 5550(b)(1) for continued listing on The NASDAQ Capital Market because the Company’s stockholders’ equity of approximately $2.2 million as reported in the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2023, is below the required minimum of $2.5 million, and as of May 22, 2023, the Company does not meet t","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326706/000149315223019096/0001493152-23-019096-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}